Mercury Laboratories Limited
BSE: MERCURYLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Mercury Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mercury Laboratories Limited is an Ahmedabad-based pharmaceutical company specialising in the manufacturing and marketing of diverse healthcare formulations. The company focuses on therapeutic segments including gynecology, pediatrics, cardiology, and orthopedics, with a strong emphasis on mother and child healthcare.
Business Model
The company generates revenue through the production and sale of generic formulations and branded specialty products, including tablets, capsules, liquid orals, and injectables. It serves both domestic and international markets, leveraging GMP-compliant manufacturing facilities to support its export operations.
Growth Outlook
Growth is driven by the expansion of its branded specialty portfolio and the strengthening of its export footprint across Africa, Southeast Asia, and Latin America. The company continues to prioritise affordable healthcare delivery to maintain its competitive position in the mid-sized pharmaceutical segment.
Key Risks
- Regulatory Compliance. Failure to maintain Good Manufacturing Practices (GMP) could lead to export restrictions or product recalls in international markets.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector may exert downward pressure on margins and profitability.
- Currency Volatility. As an exporter to emerging markets, the company is exposed to fluctuations in foreign exchange rates that may impact revenue realisation.
- Supply Chain Disruptions. Dependence on the availability and pricing of active pharmaceutical ingredients (APIs) poses a risk to consistent production cycles.
Start your research today
Unlock AI insights, financials, peers and live data on Mercury Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹78 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹35.83
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.0%
TTM · standalone
P/E
24.5x
Q4 FY26 · standalone
EV/EBITDA
10.5x
Q4 FY26 · standalone
EBITDA MARGIN
13.4%
TTM · standalone
NET PROFIT MARGIN
6.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Mercury Laboratories LimitedMERCURYLAB | ₹93 Cr | 21.59 | 9.57 | 3.3% | 13.4% | 7.9% | 11.0% | -8.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Mercury Laboratories Limited
BSE: MERCURYLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Mercury Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mercury Laboratories Limited is an Ahmedabad-based pharmaceutical company specialising in the manufacturing and marketing of diverse healthcare formulations. The company focuses on therapeutic segments including gynecology, pediatrics, cardiology, and orthopedics, with a strong emphasis on mother and child healthcare.
Business Model
The company generates revenue through the production and sale of generic formulations and branded specialty products, including tablets, capsules, liquid orals, and injectables. It serves both domestic and international markets, leveraging GMP-compliant manufacturing facilities to support its export operations.
Growth Outlook
Growth is driven by the expansion of its branded specialty portfolio and the strengthening of its export footprint across Africa, Southeast Asia, and Latin America. The company continues to prioritise affordable healthcare delivery to maintain its competitive position in the mid-sized pharmaceutical segment.
Key Risks
- Regulatory Compliance. Failure to maintain Good Manufacturing Practices (GMP) could lead to export restrictions or product recalls in international markets.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector may exert downward pressure on margins and profitability.
- Currency Volatility. As an exporter to emerging markets, the company is exposed to fluctuations in foreign exchange rates that may impact revenue realisation.
- Supply Chain Disruptions. Dependence on the availability and pricing of active pharmaceutical ingredients (APIs) poses a risk to consistent production cycles.
Start your research today
Unlock AI insights, financials, peers and live data on Mercury Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹78 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹35.83
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.0%
TTM · standalone
P/E
24.5x
Q4 FY26 · standalone
EV/EBITDA
10.5x
Q4 FY26 · standalone
EBITDA MARGIN
13.4%
TTM · standalone
NET PROFIT MARGIN
6.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26